Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Neurology

Tracking the Journey: Symptoms and Progression

At a Glance

FXTAS is a progressive neurological condition tracked by the Hagerman Staging System, ranging from mild tremors to severe mobility issues. Symptoms typically unfold over decades, involving movement challenges like intention tremor and ataxia, alongside cognitive and emotional changes.

FXTAS is a progressive condition, meaning symptoms tend to change and develop over time. While every person’s journey is unique, doctors use specific frameworks to understand how the disease is moving and what kind of support is needed at each step. Understanding these patterns can help you and your care team stay ahead of new challenges.

The Hagerman Staging System

The Hagerman Staging System is a tool used by neurologists to track the severity of FXTAS symptoms, primarily focusing on motor abilities [1]. It is important to know that progressing through these stages usually takes many years or even decades [2]. It ranges from 0 to 6:

  • Stage 0: No symptoms are present.
  • Stage 1: Subtle or questionable symptoms, such as a very slight tremor or minor balance issues.
  • Stage 2: Small but clear symptoms that do not interfere significantly with daily life.
  • Stage 3: Moderate symptoms; the person may have difficulty with some activities but can still walk without assistance.
  • Stage 4: Severe symptoms; the person now requires a cane or walker to move safely [3].
  • Stage 5: The person primarily uses a wheelchair for mobility [3].
  • Stage 6: Bedridden or requiring total care for all activities of daily living.

Motor Symptoms: The Physical Impact

The most visible signs of FXTAS involve movement. These symptoms often start subtly and worsen over years [4]. Intention tremor and cerebellar ataxia are the two “major clinical signs” doctors look for when officially diagnosing the condition [5].

  • Intention Tremor: This is a shaky movement that happens when you are reaching for something, like a glass of water or a pen [6]. It is different from the “resting tremor” often seen in Parkinson’s disease.
  • Cerebellar Ataxia: This is a lack of muscle coordination that affects balance and walking [7]. It may feel like being “clumsy” or having a “drunk-like” gait even when sober.
  • Parkinsonism: Some people develop stiffness, slow movements (bradykinesia), or a “masked” facial expression [6][8].
  • Peripheral Neuropathy: Numbness, tingling, or weakness in the hands and feet is common. If these sensory issues cause physical discomfort or pain, medications are available to help manage it [9][10].

Non-Motor Symptoms: The Cognitive & Emotional Impact

For caregivers, the non-motor symptoms can sometimes be the most challenging to manage. FXTAS affects the parts of the brain responsible for “thinking” and “feeling.”

  • Executive Dysfunction: This involves difficulty with “boss-like” brain functions: planning, organizing, multitasking, and problem-solving [11][12].
  • Psychiatric Issues: Anxiety, depression, and irritability are common and are biological symptoms of the disease [6]. In some cases, a person may experience “apathy,” where they seem to lose interest in their usual hobbies or social life [13].
  • Cognitive Decline: Over time, memory and processing speed may slow down [14].

Late-Stage Complications

As FXTAS progresses into stages 4 and 5, new health risks can emerge that require close attention.

  • Dysphagia (Swallowing Difficulties): The muscles used for swallowing can become weak or uncoordinated [15]. This can lead to frequent coughing or choking during meals.
  • Aspiration Risk: If food or liquid enters the lungs instead of the stomach, it can cause aspiration pneumonia, a serious infection [15].
  • Falls: Due to the combination of ataxia and neuropathy, the risk of serious injury from falls increases significantly in later stages [7].

Monitoring these symptoms through regular check-ups allows for early interventions, such as physical therapy for balance or speech therapy for swallowing, which can significantly improve quality of life [16][17].

Common questions in this guide

What is the Hagerman Staging System for FXTAS?
The Hagerman Staging System is a 7-point scale neurologists use to track the progression of FXTAS symptoms, particularly motor abilities. It ranges from stage 0, where no symptoms are present, to stage 6, where a person requires total care.
What kind of tremors do people with FXTAS have?
People with FXTAS typically experience an intention tremor, which is a shakiness that occurs when reaching for an object or performing a purposeful movement. This is distinctly different from the resting tremor commonly seen in Parkinson's disease.
Does FXTAS affect cognitive and emotional health?
Yes, FXTAS impacts the parts of the brain responsible for thinking and feeling. It frequently causes executive dysfunction, cognitive decline, and psychiatric symptoms such as anxiety, depression, or profound apathy.
What complications occur in the later stages of FXTAS?
As the disease advances, individuals may develop swallowing difficulties, known as dysphagia, which increases the risk of choking and aspiration pneumonia. The severe balance issues and neuropathy also significantly increase the risk of serious falls.
How can we manage the symptoms of FXTAS?
While FXTAS is a progressive condition, therapies can greatly improve quality of life. Care teams often use physical therapy for balance, speech therapy for swallowing difficulties, and medications to manage nerve pain and mood changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on your examination, what is my current Hagerman stage?
  2. 2.How often should we be screening for swallowing difficulties (dysphagia)?
  3. 3.Are the cognitive changes I'm noticing typical for this stage of FXTAS, or should we look for other causes?
  4. 4.What signs should I look for that might indicate the disease is progressing to the next stage?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Fragile X-associated tremor ataxia syndrome rating scale: Revision and content validity using a mixed method approach.

    Tosin MHS, Stebbins GT, Goetz CG, et al.

    Frontiers in neurology 2022; (13()):977380 doi:10.3389/fneur.2022.977380.

    PMID: 36188408
  2. 2

    Artificial neural network applied to fragile X-associated tremor/ataxia syndrome stage diagnosis based on peripheral mitochondrial bioenergetics and brain imaging outcomes.

    Giulivi C, Wang JY, Hagerman RJ

    Scientific reports 2022; (12(1)):21382 doi:10.1038/s41598-022-25615-2.

    PMID: 36496525
  3. 3

    Making a Difference-Positive Effect of Unilateral VIM Gamma Knife Thalamotomy in the Therapy of Tremor in Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS).

    Alster P, Koziorowski DM, Za Bek M, et al.

    Frontiers in neurology 2018; (9()):512 doi:10.3389/fneur.2018.00512.

    PMID: 29997574
  4. 4

    Fragile X-Associated Tremor/Ataxia Syndrome in a Man in His 30s.

    Martínez-Cerdeño V, Lechpammer M, Lott A, et al.

    JAMA neurology 2015; (72(9)):1070-3 doi:10.1001/jamaneurol.2015.1138.

    PMID: 26368352
  5. 5

    Fragile X-associated tremor/ataxia syndrome: An under-recognised cause of tremor and ataxia.

    Kalus S, King J, Lui E, Gaillard F

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2016; (23()):162-164 doi:10.1016/j.jocn.2015.08.010.

    PMID: 26439425
  6. 6

    Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS): Pathophysiology and Clinical Implications.

    Cabal-Herrera AM, Tassanakijpanich N, Salcedo-Arellano MJ, Hagerman RJ

    International journal of molecular sciences 2020; (21(12)) doi:10.3390/ijms21124391.

    PMID: 32575683
  7. 7

    Digital gait markers to potentially distinguish fragile X-associated tremor/ataxia syndrome, Parkinson's disease, and essential tremor.

    Robertson-Dick EE, Timm EC, Pal G, et al.

    Frontiers in neurology 2023; (14()):1308698 doi:10.3389/fneur.2023.1308698.

    PMID: 38162443
  8. 8

    Upper and Lower Limb Movement Kinematics in Aging FMR1 Gene Premutation Carriers.

    Wang Z, Lane C, Terza M, et al.

    Brain sciences 2020; (11(1)) doi:10.3390/brainsci11010013.

    PMID: 33374331
  9. 9

    A case of Fragile X-associated tremor/ataxia syndrome (FXTAS).

    Mishra SK, Khosa S, Trikamji B, et al.

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2019; (66()):269-270 doi:10.1016/j.jocn.2019.05.044.

    PMID: 31178302
  10. 10

    FXTAS is difficult to differentiate from neuronal intranuclear inclusion disease through skin biopsy: a case report.

    Toko M, Ohshita T, Kurashige T, et al.

    BMC neurology 2021; (21(1)):396 doi:10.1186/s12883-021-02425-z.

    PMID: 34641814
  11. 11

    Memantine Improves Attentional Processes in Fragile X-Associated Tremor/Ataxia Syndrome: Electrophysiological Evidence from a Randomized Controlled Trial.

    Yang JC, Rodriguez A, Royston A, et al.

    Scientific reports 2016; (6()):21719 doi:10.1038/srep21719.

    PMID: 26898832
  12. 12

    Reduced caudate volume and cognitive slowing in men at risk of fragile X-associated tremor ataxia syndrome.

    Cvejic RC, Hocking DR, Wen W, et al.

    Brain imaging and behavior 2019; (13(4)):1128-1134 doi:10.1007/s11682-018-9928-7.

    PMID: 30046972
  13. 13

    Fragile X associated neuropsychiatric disorders in a male without FXTAS.

    Cabal-Herrera AM, Saldarriaga-Gil W, Salcedo-Arellano MJ, Hagerman RJ

    Intractable & rare diseases research 2020; (9(2)):113-118 doi:10.5582/irdr.2020.01028.

    PMID: 32494560
  14. 14

    Fentanyl overdose in a female with the FMR1 premutation and FXTAS.

    El-Deeb M, Adams P, Schneider A, et al.

    Journal of molecular genetics (Isleworth, London, England) 2018; (1(1)) doi:10.31038/JMG.1000101.

    PMID: 31032490
  15. 15

    Swallowing and choking difficulties as potential markers of FXTAS progression in FMR1 premutation carriers.

    Likhitweerawong N, Montanaro FAM, Santos ER, et al.

    Scientific reports 2025; (15(1)):42164 doi:10.1038/s41598-025-25959-5.

    PMID: 41298566
  16. 16

    Clinimetric Properties of the Fragile X-associated Tremor Ataxia Syndrome Rating Scale.

    Hall DA, Stebbins GT, Jacquemont S, et al.

    Movement disorders clinical practice 2019; (6(2)):120-124 doi:10.1002/mdc3.12708.

    PMID: 30838310
  17. 17

    Biomarkers of balance and gait deficits in FMR1 premutation carriers: a mini-review.

    Moore LC, Maltman N, Lee-Confer JS, Kobel MJ

    Frontiers in aging neuroscience 2025; (17()):1637819 doi:10.3389/fnagi.2025.1637819.

    PMID: 41122346

This page provides educational information about FXTAS symptoms and disease progression. It is not medical advice. Always consult a neurologist to evaluate symptoms and determine the appropriate stage of care.

Get notified when new evidence is published on Fragile X-associated tremor/ataxia syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.